...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo
【24h】

New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo

机译:新的喹啉衍生物在体外和体内对伯氏疟原虫表现出有希望的抗疟原虫活性

获取原文
获取原文并翻译 | 示例
           

摘要

Malaria continues to be an important public health problem in the world. Nowadays, the widespread parasite resistance to many drugs used in antimalarial therapy has made the effective treatment of cases and control of the disease a constant challenge. Therefore, the discovery of new molecules with good antimalarial activity and tolerance to human use can be really important in the further treatment of the disease. In this study we have investigated the antiplasmodial activity of 10 synthetic compounds derived from quinoline, five of them combined to sulfonamide and five to the hydrazine or hydrazide group. The compounds were evaluated according to their cytotoxicity against HepG2 and HeLa cell lines, their antimalarial activity against CQ-sensitive and CQ-resistant Plasmodium falciparum strains and, finally, their schizonticide blood action in mice infected with Plasmodium berghei NK65. The compounds exhibited no cytotoxic action in HepG2 and HeLa cell lines when tested up to a concentration of 100 mu g/mL. In addition, the hydrazine or hydrazide derivative compounds were less cytotoxic against cell lines and more active against CQ-sensitive and CQ-resistant P. falciparum strains, showing high SI (> 1000 when SI was calculated using the CC50 from the 3D7 strain as reference). When tested in vivo, the hydrazine derivative 1f compound showed activity against the development of blood parasites similar to that observed with CQ, the reference drug. Interestingly, the 1f compound demonstrated the best LipE value (4.84) among all those tested in vivo. Considering the in vitro and in vivo activities of the compounds studied here and the LipE values, we believe the 1f compound to be the most promising molecule for further studies in antimalarial chemotherapy. (C) 2015 Elsevier Ltd. All rights reserved.
机译:疟疾仍然是世界上重要的公共卫生问题。如今,抗疟疾治疗中使用的许多药物对寄生虫的广泛耐药性使有效治疗病例和控制疾病成为一项持续的挑战。因此,发现具有良好抗疟疾活性和对人类使用耐受性的新分子在进一步治疗该疾病中确实很重要。在这项研究中,我们研究了10种衍生自喹啉的合成化合物的抗血浆活性,其中5种与磺酰胺结合,另外5种与肼或酰肼基结合。根据它们对HepG2和HeLa细胞系的细胞毒性,对CQ敏感和CQ耐药的恶性疟原虫菌株的抗疟疾活性以及最终在感染了伯氏疟原虫NK65的小鼠中的除chi剂的血液作用进行了评估。当测试浓度达到100μg / mL时,这些化合物在HepG2和HeLa细胞系中没有细胞毒性作用。此外,肼或酰肼衍生物化合物对细胞系的细胞毒性较小,并且对CQ敏感和CQ耐药的恶性疟原虫菌株更具活性,显示出较高的SI(> 1000(当使用3D7菌株的CC50计算SI时,SI较高) )。当在体内进行测试时,肼衍生物1f化合物显示出对抗血寄生虫的活性,与参考药物CQ相似。有趣的是,在所有体内测试的化合物中,1f化合物表现出最佳的LipE值(4.84)。考虑到此处研究的化合物的体外和体内活性以及LipE值,我们认为1f化合物是抗疟化疗中进一步研究的最有希望的分子。 (C)2015 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号